| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/02/2003 | US20030003447 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/02/2003 | US20030003143 Lipidic microparticles linked to multiple proteins |
| 01/02/2003 | US20030003114 Hexosaminidase covalently attached to a cancer cell targeting ligand; improves selectively of the hexosaminidase for tumor cells |
| 01/02/2003 | US20030003112 Avipox virus containing foreign DNA from porcine reproductive and respiratory syndrome virus; immunological compositions containing the recombinant poxvirus for inducing an immunological response in a host animal |
| 01/02/2003 | US20030003103 Sequences for targeting metastatic cells |
| 01/02/2003 | US20030003100 Gene therapy strategy, comprising an antibody-nucleic acid-cationic macromolecule complex that enhances nucleic acid delivery to mammalian cells |
| 01/02/2003 | US20030003092 Administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present |
| 01/02/2003 | US20030003088 A human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of produce insulin; treating insulin-dependent diabetes; determining a chemical agent to induce cell differentiation |
| 01/02/2003 | US20030003087 Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system |
| 01/02/2003 | US20030003086 A genetic engineered cell comprising an exogenously derived nucleic acid coding for a thimet oligopeptidase (TOP) polypeptide; modulate antigen presentation on cell surfaces, works synergistically with immunosuppressive drugs |
| 01/02/2003 | US20030003085 Drug delivery of a muscle protein by administering purified donor muscle side population cells; gene therapy, in the treatment muscle diseases muscular dystrophies, genetic diseases, treating cancer, and bone marrow transplant |
| 01/02/2003 | US20030003079 Recombinant pox virus for immunization against tumor-associated antigens |
| 01/02/2003 | US20030003077 A genetic engineered adenoviral vector contains an adenoviral genome from which the open reading frames E1 and/or E3 were deleted and a therapeutic gene or a DNA sequence that encodes for therapeutic proteins useful in fibrosis treatment |
| 01/02/2003 | US20030003076 Adenovirus E1B-55K single amino acid mutants and methods of use |
| 01/02/2003 | EP1271153A2 Collapsin response mediator protein-1 as tumor metastasis marker |
| 01/02/2003 | EP1271146A1 Method and composition of cellular reprogramming |
| 01/02/2003 | EP1270732A1 Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| 01/02/2003 | EP1270719A2 Cell population containing non-fetal hemangioblasts and method for producing same |
| 01/02/2003 | EP1270586A2 Composition for the cell-specific transfer of active substances |
| 01/02/2003 | EP1270044A2 Wound healing biomarkers |
| 01/02/2003 | EP1270016A1 Aids virus vaccine with the use of sendai virus vector |
| 01/02/2003 | EP1270015A2 A complex comprising OCIF and Polysaccharide |
| 01/02/2003 | EP1270000A2 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis |
| 01/02/2003 | EP1268861A2 Diagnosis of diseases associated with dna transcription |
| 01/02/2003 | EP1268857A2 Diagnosis of diseases associated with gene regulation |
| 01/02/2003 | EP1268855A2 Diagnosis of diseases associated with tumor suppressor genes and oncogenes |
| 01/02/2003 | EP1268854A1 High specificity marker detection |
| 01/02/2003 | EP1268835A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| 01/02/2003 | EP1268833A2 Modified nodavirus rna for gene delivery |
| 01/02/2003 | EP1268817A1 Human pyruvate dehydrogenese phosphatase |
| 01/02/2003 | EP1268812A2 Vectors for gene therapy |
| 01/02/2003 | EP1268806A1 Clostridium difficile polypeptides and uses thereof |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268799A2 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268795A2 Regulation of human mas oncogene-related g protein-coupled receptor |
| 01/02/2003 | EP1268792A2 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 01/02/2003 | EP1268791A2 Brca-1 regulators and methods of use |
| 01/02/2003 | EP1268790A1 Gene coding for erbin, and diagnostic and therapeutic uses thereof |
| 01/02/2003 | EP1268787A2 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 01/02/2003 | EP1268785A2 Gtp-binding protein gamma-12 subunit |
| 01/02/2003 | EP1268784A2 Genes involved in intestinal inflammatory diseases and use thereof |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268778A1 Materials and methods relating to a novel splice variant of a na + dependent glutamate transporter |
| 01/02/2003 | EP1268775A1 The high bone mass gene of 11q13.3 |
| 01/02/2003 | EP1268774A2 Identification of essential genes in prokaryotes |
| 01/02/2003 | EP1268773A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 01/02/2003 | EP1268772A2 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 01/02/2003 | EP1268771A1 Human gata-5 transcription factor |
| 01/02/2003 | EP1268768A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/02/2003 | EP1268761A2 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
| 01/02/2003 | EP1268759A2 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 01/02/2003 | EP1268555A2 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 01/02/2003 | EP1268548A2 Regulation of human rta-like g protein-coupled receptor |
| 01/02/2003 | EP1268547A2 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 01/02/2003 | EP1268543A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268542A2 Therapeutic anti-melanoma compounds |
| 01/02/2003 | EP1268541A1 7 human ovarian and ovarian cancer associated proteins |
| 01/02/2003 | EP1268540A2 Proteins amf-1 to amf-10 and nucleic acids encoding same |
| 01/02/2003 | EP1268539A2 Estrogen-regulated unconventional myosin-related protein: compositions and methods of use |
| 01/02/2003 | EP1268536A1 Tcf responsive element |
| 01/02/2003 | EP1268530A1 Hepatitis b core antigen fusion proteins |
| 01/02/2003 | EP1268528A2 Human genes and expression products |
| 01/02/2003 | EP1268510A2 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268507A1 Antisense modulation of e2f transcription factor 1 expression |
| 01/02/2003 | EP1267954A1 Medical devices suitable for gene therapy regimens |
| 01/02/2003 | EP1267945A2 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor |
| 01/02/2003 | EP1267944A1 Systemic gene delivery vehicles for the treatment of tumors |
| 01/02/2003 | EP1267933A2 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 01/02/2003 | EP1267924A2 Immunotherapeutic methods and compositions |
| 01/02/2003 | EP1267917A1 Angiogenic onchocerca volvulus proteins and uses thereof |
| 01/02/2003 | EP1267914A1 Use of lyosomal acid lipase for treating atherosclerosis and related diseases |
| 01/02/2003 | EP1267910A2 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 01/02/2003 | EP1267899A2 Salmonella vaccine materials and methods |
| 01/02/2003 | EP1267834A1 Cationic liposomes |
| 01/02/2003 | EP1267800A1 Methods of modulating hair growth |
| 01/02/2003 | EP1267616A1 Methods of modulating hair growth |
| 01/02/2003 | EP1115886A4 Secreted renilla luciferase |
| 01/02/2003 | EP0930896B1 Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
| 01/02/2003 | EP0745131B1 Targeting gene therapy |
| 01/02/2003 | EP0723440B1 Therapeutic delivery compositions and methods of use thereof |
| 01/01/2003 | CN1388829A High efficiency retroviral vector which contains genetically engineered cellular non-coding sequence harboring splicing acceptor |
| 01/01/2003 | CN1388248A Adenovirus proliferated specifically inside tumor cell to express interferon in high efficiency and its construction method |
| 01/01/2003 | CN1388247A Method of strengthening specific destination gene expression of cell |
| 01/01/2003 | CN1097634C Interleukin-6 active inhibitor |
| 12/31/2002 | USRE37952 Grb3-3 cDNA and polypeptides |
| 12/31/2002 | US6500945 Nucleotides having chiral phosphorus linkages |
| 12/31/2002 | US6500941 Secreted by human breast cancer mda-mb-175 cells, leads to the formation of a constitutive active receptor complex and stimulates these cells in an autocrine manner |
| 12/31/2002 | US6500937 Plasmid or vector; sequence encodes mammastatin; useful in the diagnosis and treatment of breast cancer |
| 12/31/2002 | US6500919 Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma |
| 12/31/2002 | US6500807 Gene therapy |
| 12/31/2002 | US6500662 Infectious cdna clones of positive polarity rna viruses and the construction of vaccines, in particular, swine vaccines, using such cdna clones |
| 12/31/2002 | US6500641 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, |
| 12/31/2002 | US6500436 Administering botulinium toxin component coupled to substance p |
| 12/31/2002 | US6500432 Method to enhance an immune response of nucleic acid vaccination |
| 12/31/2002 | US6500422 Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3) |
| 12/31/2002 | US6500421 Combination of the antifolate and the nucleoside transport inhibitor selects in vivo for the genetically modified hematopoietic progenitor cells |
| 12/31/2002 | US6500419 Method for introducing and expressing RNA in animal cells |
| 12/29/2002 | CA2392383A1 A complex comprising ocif and polysaccharide |